Global Antimicrobial Therapeutics Market By Drug Class, By Route of Administration, By Disease Indication, By Spectrum of Activity, By Region: Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Global Antimicrobial Therapeutics Market was Valued at US$ 208.75 Billion in 2022, Growing at an Estimated CAGR of 4.8% from 2023-2031
Antimicrobial therapeutics are a class of medical interventions aimed at combating microbial infections, such as bacteria, viruses, fungi, and parasites. These treatments encompass a diverse range of approaches, including antibiotics, antiviral drugs, antifungal agents, and antiparasitic medications. They work by either directly killing the infectious organisms or inhibiting their growth and reproduction. The effectiveness of antimicrobial therapies can be influenced by factors like drug resistance, patient-specific characteristics, and the type of infection. Proper use of this therapeutics is crucial to prevent the emergence of resistant strains and ensure effective treatment. Ongoing research and development are essential to address the evolving challenges posed by microbial infections and to discover novel approaches for combating them.
Antibacterials, which include antibiotics, are a dominant category in the antimicrobial therapeutics market, due to the widespread prevalence of bacterial infections. They have historically held a significant share in the market due to their extensive use in treating various bacterial illnesses. Despite challenges like antibiotic resistance, new antibiotic development continues to support the dominance of this category.
COVID-19 Impact Analysis on Global Antimicrobial Therapeutics Market
Lockdowns, travel restrictions, and manufacturing disruptions caused supply chain challenges, affecting the production and distribution of antimicrobial drugs. This led to shortages and delays in drug availability. The post-pandemic impact is expected to be even more pronounced. The COVID-19 pandemic has exerted a transformative impact on the antimicrobial therapeutics market, spurring novel approaches, rapid collaborations, and innovative research to address both viral infections and the broader context of antimicrobial resistance.
Global Antimicrobial Therapeutics Market Revenue & Forecast, (US$ Million), 2015 – 2031
The rise of antibiotic-resistant bacterial strains remains a major driver. An estimated 700,000 deaths globally are attributed to antibiotic resistance annually. This compels the development of new antimicrobial therapeutics to combat resistant infections. The urgent need is evident as multi-drug resistant infections are projected to cause over 10 million deaths per year by 2050 if unaddressed, emphasizing the demand for innovative treatments. A restraint in the antimicrobial therapeutics market is the lengthy drug development process. The drug development process for antimicrobial therapeutics is notably protracted, averaging 10-15 years. This extended timeline stems from rigorous clinical trials, regulatory hurdles, and the evolving nature of infectious diseases. The result is increased costs and delays in bringing new treatments to market. This impedes timely responses to emerging infectious threats and hampers market growth.
Broad-spectrum antimicrobials have historically dominated the market due to their versatility and initial effectiveness against a broad array of infections. They cover a wide range of pathogens, which include both gram-positive and gram-negative bacteria. However, their broad action can contribute to antibiotic resistance and disrupt the natural microbiota.
North America recorded highest market share in the global antimicrobial therapeutics market in 2022. This is due to its robust healthcare infrastructure and high disease burden. The region spends a substantial amount on healthcare, with the United States accounting for around 16% of its GDP on healthcare expenditures. This emphasis on healthcare has historically driven the demand for antimicrobial therapies to address prevalent infections.
Competitive Landscape
The report provides both, qualitative and quantitative research of global antimicrobial therapeutics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global antimicrobial therapeutics market are
- AbbVie Inc.
- Allergan
- AstraZeneca
- Bayer AG
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- GSK plc
- Johnson & Johnson Services, Inc.
- Lilly
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Other Industry Participants
Global Antimicrobial Therapeutics Market:
By Drug Class
- Antibacterials
- Antivirals
- Antifungals
- Antiparasitic
By Route of Administration
- Oral
- Topical
- Injectable
- Others
By Disease Indication
- Respiratory Infections
- Urinary Tract Infections (UTIs)
- Skin and Soft Tissue Infections
- Sexually Transmitted Infections (STIs)
- Gastrointestinal Infections
- Central Nervous System Infections
- Others
By Spectrum of Activity
- Broad-spectrum
- Narrow-spectrum
By End User
- Hospitals and Clinics
- Homecare
- Research Institutes
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2022
1.2.3. Forecast Years: 2023 – 2031
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Antimicrobial Therapeutics Market
6.
Market
Synopsis: Antimicrobial Therapeutics
Market
7.
Antimicrobial
Therapeutics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Antimicrobial Therapeutics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Antimicrobial Therapeutics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Antimicrobial
Therapeutics Market
7.8. PESTEL Analysis
8.
Global
Antimicrobial Therapeutics Market Analysis and Forecasts, 2023 - 2031
8.1. Overview
8.1.1. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn)
8.2. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
8.2.1. Antibacterials
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.1.3.
Market
Forecast, 2023 - 2031
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2022
8.2.1.5.1.2. Market Forecast, 2023 - 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2022
8.2.1.5.2.2. Market Forecast, 2023 - 2031
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2022
8.2.1.5.3.2. Market Forecast, 2023 - 2031
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2022
8.2.1.5.4.2. Market Forecast, 2023 - 2031
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2022
8.2.1.5.5.2. Market Forecast, 2023 - 2031
8.2.2. Antivirals
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.2.3.
Market
Forecast, 2023 - 2031
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2022
8.2.2.5.1.2. Market Forecast, 2023 - 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2022
8.2.2.5.2.2. Market Forecast, 2023 - 2031
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2022
8.2.2.5.3.2. Market Forecast, 2023 - 2031
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2022
8.2.2.5.4.2. Market Forecast, 2023 - 2031
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2022
8.2.2.5.5.2. Market Forecast, 2023 - 2031
8.2.3. Antifungals
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.3.3.
Market
Forecast, 2023 - 2031
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2022
8.2.3.5.1.2. Market Forecast, 2023 - 2031
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2022
8.2.3.5.2.2. Market Forecast, 2023 - 2031
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2022
8.2.3.5.3.2. Market Forecast, 2023 - 2031
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2022
8.2.3.5.4.2. Market Forecast, 2023 - 2031
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2022
8.2.3.5.5.2. Market Forecast, 2023 - 2031
8.2.4. Antiparasitic
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.4.3.
Market
Forecast, 2023 - 2031
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2022
8.2.4.5.1.2. Market Forecast, 2023 - 2031
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2022
8.2.4.5.2.2. Market Forecast, 2023 - 2031
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2022
8.2.4.5.3.2. Market Forecast, 2023 - 2031
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2022
8.2.4.5.4.2. Market Forecast, 2023 - 2031
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2022
8.2.4.5.5.2. Market Forecast, 2023 - 2031
8.3. Key Segment for Channeling Investments
8.3.1. By Drug Class
9.
Global
Antimicrobial Therapeutics Market Analysis and Forecasts, 2023 - 2031
9.1. Overview
9.2. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
9.2.1. Oral
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.1.3.
Market
Forecast, 2023 - 2031
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2022
9.2.1.5.1.2. Market Forecast, 2023 - 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2022
9.2.1.5.2.2. Market Forecast, 2023 - 2031
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2022
9.2.1.5.3.2. Market Forecast, 2023 - 2031
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2022
9.2.1.5.4.2. Market Forecast, 2023 - 2031
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2022
9.2.1.5.5.2. Market Forecast, 2023 - 2031
9.2.2. Topical
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.2.3.
Market
Forecast, 2023 - 2031
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2022
9.2.2.5.1.2. Market Forecast, 2023 - 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2022
9.2.2.5.2.2. Market Forecast, 2023 - 2031
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2022
9.2.2.5.3.2. Market Forecast, 2023 - 2031
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2022
9.2.2.5.4.2. Market Forecast, 2023 - 2031
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2022
9.2.2.5.5.2. Market Forecast, 2023 - 2031
9.2.3. Injectable
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.3.3.
Market
Forecast, 2023 - 2031
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2022
9.2.3.5.1.2. Market Forecast, 2023 - 2031
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2022
9.2.3.5.2.2. Market Forecast, 2023 - 2031
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2022
9.2.3.5.3.2. Market Forecast, 2023 - 2031
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2022
9.2.3.5.4.2. Market Forecast, 2023 - 2031
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2022
9.2.3.5.5.2. Market Forecast, 2023 - 2031
9.2.4. Others
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.4.3.
Market
Forecast, 2023 - 2031
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2022
9.2.4.5.1.2. Market Forecast, 2023 - 2031
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2022
9.2.4.5.2.2. Market Forecast, 2023 - 2031
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2022
9.2.4.5.3.2. Market Forecast, 2023 - 2031
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2022
9.2.4.5.4.2. Market Forecast, 2023 - 2031
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2022
9.2.4.5.5.2. Market Forecast, 2023 - 2031
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global Antimicrobial Therapeutics Market
Analysis and Forecasts, 2023 - 2031
10.1. Overview
10.2. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
10.2.1. Respiratory Infections
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.1.3.
Market
Forecast, 2023 - 2031
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2022
10.2.1.5.1.2. Market Forecast, 2023 - 2031
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2022
10.2.1.5.2.2. Market Forecast, 2023 - 2031
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2022
10.2.1.5.3.2. Market Forecast, 2023 - 2031
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2022
10.2.1.5.4.2. Market Forecast, 2023 - 2031
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2022
10.2.1.5.5.2. Market Forecast, 2023 - 2031
10.2.2. Urinary Tract Infections (UTIs)
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.2.3.
Market
Forecast, 2023 - 2031
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2022
10.2.2.5.1.2. Market Forecast, 2023 - 2031
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2022
10.2.2.5.2.2. Market Forecast, 2023 - 2031
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2022
10.2.2.5.3.2. Market Forecast, 2023 - 2031
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2022
10.2.2.5.4.2. Market Forecast, 2023 - 2031
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2022
10.2.2.5.5.2. Market Forecast, 2023 - 2031
10.2.3. Skin and Soft Tissue Infections
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.3.3.
Market
Forecast, 2023 - 2031
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2022
10.2.3.5.1.2. Market Forecast, 2023 - 2031
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2022
10.2.3.5.2.2. Market Forecast, 2023 - 2031
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2022
10.2.3.5.3.2. Market Forecast, 2023 - 2031
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2022
10.2.3.5.4.2. Market Forecast, 2023 - 2031
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2022
10.2.3.5.5.2. Market Forecast, 2023 - 2031
10.2.4. Sexually Transmitted Infections (STIs)
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.4.3.
Market
Forecast, 2023 - 2031
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1.
North
America
10.2.4.5.1.1. Market Estimation, 2015 - 2022
10.2.4.5.1.2. Market Forecast, 2023 - 2031
10.2.4.5.2.
Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2022
10.2.4.5.2.2. Market Forecast, 2023 - 2031
10.2.4.5.3.
Asia
Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2022
10.2.4.5.3.2. Market Forecast, 2023 - 2031
10.2.4.5.4.
Middle
East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2022
10.2.4.5.4.2. Market Forecast, 2023 - 2031
10.2.4.5.5.
Latin
America
10.2.4.5.5.1. Market Estimation, 2015 - 2022
10.2.4.5.5.2. Market Forecast, 2023 - 2031
10.2.5. Gastrointestinal Infections
10.2.5.1.
Definition
10.2.5.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.5.3.
Market
Forecast, 2023 - 2031
10.2.5.4.
Compound
Annual Growth Rate (CAGR)
10.2.5.5.
Regional
Bifurcation
10.2.5.5.1.
North
America
10.2.5.5.1.1. Market Estimation, 2015 - 2022
10.2.5.5.1.2. Market Forecast, 2023 - 2031
10.2.5.5.2.
Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2022
10.2.5.5.2.2. Market Forecast, 2023 - 2031
10.2.5.5.3.
Asia
Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2022
10.2.5.5.3.2. Market Forecast, 2023 - 2031
10.2.5.5.4.
Middle
East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2022
10.2.5.5.4.2. Market Forecast, 2023 - 2031
10.2.5.5.5.
Latin
America
10.2.5.5.5.1. Market Estimation, 2015 - 2022
10.2.5.5.5.2. Market Forecast, 2023 - 2031
10.2.6. Central Nervous System Infections
10.2.6.1.
Definition
10.2.6.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.6.3.
Market
Forecast, 2023 - 2031
10.2.6.4.
Compound
Annual Growth Rate (CAGR)
10.2.6.5.
Regional
Bifurcation
10.2.6.5.1.
North
America
10.2.6.5.1.1. Market Estimation, 2015 - 2022
10.2.6.5.1.2. Market Forecast, 2023 - 2031
10.2.6.5.2.
Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2022
10.2.6.5.2.2. Market Forecast, 2023 - 2031
10.2.6.5.3.
Asia
Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2022
10.2.6.5.3.2. Market Forecast, 2023 - 2031
10.2.6.5.4.
Middle
East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2022
10.2.6.5.4.2. Market Forecast, 2023 - 2031
10.2.6.5.5.
Latin
America
10.2.6.5.5.1. Market Estimation, 2015 - 2022
10.2.6.5.5.2. Market Forecast, 2023 - 2031
10.2.7. Others
10.2.7.1.
Definition
10.2.7.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.7.3.
Market
Forecast, 2023 - 2031
10.2.7.4.
Compound
Annual Growth Rate (CAGR)
10.2.7.5.
Regional
Bifurcation
10.2.7.5.1.
North
America
10.2.7.5.1.1. Market Estimation, 2015 - 2022
10.2.7.5.1.2. Market Forecast, 2023 - 2031
10.2.7.5.2.
Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2022
10.2.7.5.2.2. Market Forecast, 2023 - 2031
10.2.7.5.3.
Asia
Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2022
10.2.7.5.3.2. Market Forecast, 2023 - 2031
10.2.7.5.4.
Middle
East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2022
10.2.7.5.4.2. Market Forecast, 2023 - 2031
10.2.7.5.5.
Latin
America
10.2.7.5.5.1. Market Estimation, 2015 - 2022
10.2.7.5.5.2. Market Forecast, 2023 - 2031
10.3. Key Segment for Channeling Investments
10.3.1. By Disease Indication
11. Global Antimicrobial Therapeutics Market
Analysis and Forecasts, 2023 - 2031
11.1. Overview
11.2. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
11.2.1. Broad-spectrum
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.1.3.
Market
Forecast, 2023 - 2031
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2022
11.2.1.5.1.2. Market Forecast, 2023 - 2031
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2022
11.2.1.5.2.2. Market Forecast, 2023 - 2031
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2022
11.2.1.5.3.2. Market Forecast, 2023 - 2031
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2022
11.2.1.5.4.2. Market Forecast, 2023 - 2031
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2022
11.2.1.5.5.2. Market Forecast, 2023 - 2031
11.2.2. Narrow-spectrum
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.2.3.
Market
Forecast, 2023 - 2031
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2022
11.2.2.5.1.2. Market Forecast, 2023 - 2031
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2022
11.2.2.5.2.2. Market Forecast, 2023 - 2031
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2022
11.2.2.5.3.2. Market Forecast, 2023 - 2031
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2022
11.2.2.5.4.2. Market Forecast, 2023 - 2031
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2022
11.2.2.5.5.2. Market Forecast, 2023 - 2031
11.3. Key Segment for Channeling Investments
11.3.1. By Spectrum of Activity
12. Global Antimicrobial Therapeutics Market
Analysis and Forecasts, 2023 - 2031
12.1. Overview
12.2. Global Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End User
12.2.1. Hospitals and Clinics
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
12.2.1.3.
Market
Forecast, 2023 - 2031
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2022
12.2.1.5.1.2. Market Forecast, 2023 - 2031
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2022
12.2.1.5.2.2. Market Forecast, 2023 - 2031
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2022
12.2.1.5.3.2. Market Forecast, 2023 - 2031
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2022
12.2.1.5.4.2. Market Forecast, 2023 - 2031
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2022
12.2.1.5.5.2. Market Forecast, 2023 - 2031
12.2.2. Homecare
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
12.2.2.3.
Market
Forecast, 2023 - 2031
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2022
12.2.2.5.1.2. Market Forecast, 2023 - 2031
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2022
12.2.2.5.2.2. Market Forecast, 2023 - 2031
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2022
12.2.2.5.3.2. Market Forecast, 2023 - 2031
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2022
12.2.2.5.4.2. Market Forecast, 2023 - 2031
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2022
12.2.2.5.5.2. Market Forecast, 2023 - 2031
12.2.3. Research Institutes
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
12.2.3.3.
Market
Forecast, 2023 - 2031
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1.
North
America
12.2.3.5.1.1. Market Estimation, 2015 - 2022
12.2.3.5.1.2. Market Forecast, 2023 - 2031
12.2.3.5.2.
Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2022
12.2.3.5.2.2. Market Forecast, 2023 - 2031
12.2.3.5.3.
Asia
Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2022
12.2.3.5.3.2. Market Forecast, 2023 - 2031
12.2.3.5.4.
Middle
East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2022
12.2.3.5.4.2. Market Forecast, 2023 - 2031
12.2.3.5.5.
Latin
America
12.2.3.5.5.1. Market Estimation, 2015 - 2022
12.2.3.5.5.2. Market Forecast, 2023 - 2031
12.3. Key Segment for Channeling Investments
12.3.1. By End User
13. North America Antimicrobial Therapeutics
Market Analysis and Forecasts, 2023 - 2031
13.1. Overview
13.1.1. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn)
13.2. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.2.1. Antibacterials
13.2.2. Antivirals
13.2.3. Antifungals
13.2.4. Antiparasitic
13.3. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.3.1. Oral
13.3.2. Topical
13.3.3. Injectable
13.3.4. Others
13.4. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
13.4.1. Respiratory Infections
13.4.2. Urinary Tract Infections (UTIs)
13.4.3. Skin and Soft Tissue Infections
13.4.4. Sexually Transmitted Infections (STIs)
13.4.5. Gastrointestinal Infections
13.4.6. Central Nervous System Infections
13.4.7. Others
13.5. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
13.5.1. Broad-spectrum
13.5.2. Narrow-spectrum
13.6. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End User
13.6.1. Hospitals and Clinics
13.6.2. Homecare
13.6.3. Research Institutes
13.7. North America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.1.1.1.
Antibacterials
13.7.1.1.2.
Antivirals
13.7.1.1.3.
Antifungals
13.7.1.1.4.
Antiparasitic
13.7.1.2.
U.S
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.1.2.1.
Oral
13.7.1.2.2.
Topical
13.7.1.2.3.
Injectable
13.7.1.2.4.
Others
13.7.1.3.
U.S
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.1.3.1.
Respiratory
Infections
13.7.1.3.2.
Urinary
Tract Infections (UTIs)
13.7.1.3.3.
Skin and
Soft Tissue Infections
13.7.1.3.4.
Sexually
Transmitted Infections (STIs)
13.7.1.3.5.
Gastrointestinal
Infections
13.7.1.3.6.
Central
Nervous System Infections
13.7.1.3.7.
Others
13.7.1.4.
U.S
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
13.7.1.4.1.
Broad-spectrum
13.7.1.4.2.
Narrow-spectrum
13.7.1.5.
U.S
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.1.5.1.
Hospitals
and Clinics
13.7.1.5.2.
Homecare
13.7.1.5.3.
Research
Institutes
13.7.2. Canada
13.7.2.1.
Canada
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.2.1.1.
Antibacterials
13.7.2.1.2.
Antivirals
13.7.2.1.3.
Antifungals
13.7.2.1.4.
Antiparasitic
13.7.2.2.
Canada
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.2.2.1.
Oral
13.7.2.2.2.
Topical
13.7.2.2.3.
Injectable
13.7.2.2.4.
Others
13.7.2.3.
Canada
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.2.3.1.
Respiratory
Infections
13.7.2.3.2.
Urinary
Tract Infections (UTIs)
13.7.2.3.3.
Skin and
Soft Tissue Infections
13.7.2.3.4.
Sexually
Transmitted Infections (STIs)
13.7.2.3.5.
Gastrointestinal
Infections
13.7.2.3.6.
Central
Nervous System Infections
13.7.2.3.7.
Others
13.7.2.4.
Canada
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
13.7.2.4.1.
Broad-spectrum
13.7.2.4.2.
Narrow-spectrum
13.7.2.5.
Canada
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.2.5.1.
Hospitals
and Clinics
13.7.2.5.2.
Homecare
13.7.2.5.3.
Research
Institutes
13.7.3. Mexico
13.7.3.1.
Mexico
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.3.1.1.
Antibacterials
13.7.3.1.2.
Antivirals
13.7.3.1.3.
Antifungals
13.7.3.1.4.
Antiparasitic
13.7.3.2.
Mexico
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.3.2.1.
Oral
13.7.3.2.2.
Topical
13.7.3.2.3.
Injectable
13.7.3.2.4.
Others
13.7.3.3.
Mexico
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.3.3.1.
Respiratory
Infections
13.7.3.3.2.
Urinary
Tract Infections (UTIs)
13.7.3.3.3.
Skin and
Soft Tissue Infections
13.7.3.3.4.
Sexually
Transmitted Infections (STIs)
13.7.3.3.5.
Gastrointestinal
Infections
13.7.3.3.6.
Central
Nervous System Infections
13.7.3.3.7.
Others
13.7.3.4.
Mexico
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
13.7.3.4.1.
Broad-spectrum
13.7.3.4.2.
Narrow-spectrum
13.7.3.5.
Mexico
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
13.7.3.5.1.
Hospitals
and Clinics
13.7.3.5.2.
Homecare
13.7.3.5.3.
Research
Institutes
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Drug Class
13.7.4.1.1.
Antibacterials
13.7.4.1.2.
Antivirals
13.7.4.1.3.
Antifungals
13.7.4.1.4.
Antiparasitic
13.7.4.2.
Rest of
North America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
13.7.4.2.1.
Oral
13.7.4.2.2.
Topical
13.7.4.2.3.
Injectable
13.7.4.2.4.
Others
13.7.4.3.
Rest of
North America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
13.7.4.3.1.
Respiratory
Infections
13.7.4.3.2.
Urinary
Tract Infections (UTIs)
13.7.4.3.3.
Skin and
Soft Tissue Infections
13.7.4.3.4.
Sexually
Transmitted Infections (STIs)
13.7.4.3.5.
Gastrointestinal
Infections
13.7.4.3.6.
Central
Nervous System Infections
13.7.4.3.7.
Others
13.7.4.4.
Rest of
North America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Spectrum of Activity
13.7.4.4.1.
Broad-spectrum
13.7.4.4.2.
Narrow-spectrum
13.7.4.5.
Rest of
North America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By End User
13.7.4.5.1.
Hospitals
and Clinics
13.7.4.5.2.
Homecare
13.7.4.5.3.
Research
Institutes
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Route of Administration
13.8.4. By Disease Indication
13.8.5. By Spectrum of Activity
13.8.6. By End User
14. Europe Antimicrobial Therapeutics Market
Analysis and Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn)
14.2. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Drug Class
14.2.1. Antibacterials
14.2.2. Antivirals
14.2.3. Antifungals
14.2.4. Antiparasitic
14.3. Europe Antimicrobial Therapeutics Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.3.1. Oral
14.3.2. Topical
14.3.3. Injectable
14.3.4. Others
14.4. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Disease Indication
14.4.1. Respiratory Infections
14.4.2. Urinary Tract Infections (UTIs)
14.4.3. Skin and Soft Tissue Infections
14.4.4. Sexually Transmitted Infections (STIs)
14.4.5. Gastrointestinal Infections
14.4.6. Central Nervous System Infections
14.4.7. Others
14.5. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
14.5.1. Broad-spectrum
14.5.2. Narrow-spectrum
14.6. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By End User
14.6.1. Hospitals and Clinics
14.6.2. Homecare
14.6.3. Research Institutes
14.7. Europe Antimicrobial Therapeutics Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.1.1.1.
Antibacterials
14.7.1.1.2.
Antivirals
14.7.1.1.3.
Antifungals
14.7.1.1.4.
Antiparasitic
14.7.1.2.
France
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.1.2.1.
Oral
14.7.1.2.2.
Topical
14.7.1.2.3.
Injectable
14.7.1.2.4.
Others
14.7.1.3.
France Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease Indication
14.7.1.3.1.
Respiratory
Infections
14.7.1.3.2.
Urinary
Tract Infections (UTIs)
14.7.1.3.3.
Skin and
Soft Tissue Infections
14.7.1.3.4.
Sexually
Transmitted Infections (STIs)
14.7.1.3.5.
Gastrointestinal
Infections
14.7.1.3.6.
Central Nervous
System Infections
14.7.1.3.7.
Others
14.7.1.4.
France
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
14.7.1.4.1.
Broad-spectrum
14.7.1.4.2.
Narrow-spectrum
14.7.1.5.
France
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.5.1.
Hospitals
and Clinics
14.7.1.5.2.
Homecare
14.7.1.5.3.
Research
Institutes
14.7.2. The UK
14.7.2.1.
The UK
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.2.1.1.
Antibacterials
14.7.2.1.2.
Antivirals
14.7.2.1.3.
Antifungals
14.7.2.1.4.
Antiparasitic
14.7.2.2.
The UK
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.2.2.1.
Oral
14.7.2.2.2.
Topical
14.7.2.2.3.
Injectable
14.7.2.2.4.
Others
14.7.2.3.
The UK
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.2.3.1.
Respiratory
Infections
14.7.2.3.2.
Urinary
Tract Infections (UTIs)
14.7.2.3.3.
Skin and
Soft Tissue Infections
14.7.2.3.4.
Sexually
Transmitted Infections (STIs)
14.7.2.3.5.
Gastrointestinal
Infections
14.7.2.3.6.
Central
Nervous System Infections
14.7.2.3.7.
Others
14.7.2.4.
The UK
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
14.7.2.4.1.
Broad-spectrum
14.7.2.4.2.
Narrow-spectrum
14.7.2.5.
The UK
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.2.5.1.
Hospitals
and Clinics
14.7.2.5.2.
Homecare
14.7.2.5.3.
Research
Institutes
14.7.3. Spain
14.7.3.1.
Spain
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.3.1.1.
Antibacterials
14.7.3.1.2.
Antivirals
14.7.3.1.3.
Antifungals
14.7.3.1.4.
Antiparasitic
14.7.3.2.
Spain
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.3.2.1.
Oral
14.7.3.2.2.
Topical
14.7.3.2.3.
Injectable
14.7.3.2.4.
Others
14.7.3.3.
Spain
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.3.3.1.
Respiratory
Infections
14.7.3.3.2.
Urinary
Tract Infections (UTIs)
14.7.3.3.3.
Skin and
Soft Tissue Infections
14.7.3.3.4.
Sexually
Transmitted Infections (STIs)
14.7.3.3.5.
Gastrointestinal
Infections
14.7.3.3.6.
Central
Nervous System Infections
14.7.3.3.7.
Others
14.7.3.4.
Spain
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
14.7.3.4.1.
Broad-spectrum
14.7.3.4.2.
Narrow-spectrum
14.7.3.5.
Spain
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.3.5.1.
Hospitals
and Clinics
14.7.3.5.2.
Homecare
14.7.3.5.3.
Research
Institutes
14.7.4. Germany
14.7.4.1.
Germany
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.4.1.1.
Antibacterials
14.7.4.1.2.
Antivirals
14.7.4.1.3.
Antifungals
14.7.4.1.4.
Antiparasitic
14.7.4.2.
Germany
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.4.2.1.
Oral
14.7.4.2.2.
Topical
14.7.4.2.3.
Injectable
14.7.4.2.4.
Others
14.7.4.3.
Germany
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.4.3.1.
Respiratory
Infections
14.7.4.3.2.
Urinary
Tract Infections (UTIs)
14.7.4.3.3.
Skin and
Soft Tissue Infections
14.7.4.3.4.
Sexually
Transmitted Infections (STIs)
14.7.4.3.5.
Gastrointestinal
Infections
14.7.4.3.6.
Central
Nervous System Infections
14.7.4.3.7.
Others
14.7.4.4.
Germany
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
14.7.4.4.1.
Broad-spectrum
14.7.4.4.2.
Narrow-spectrum
14.7.4.5.
Germany
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.4.5.1.
Hospitals
and Clinics
14.7.4.5.2.
Homecare
14.7.4.5.3.
Research
Institutes
14.7.5. Italy
14.7.5.1.
Italy Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.5.1.1.
Antibacterials
14.7.5.1.2.
Antivirals
14.7.5.1.3.
Antifungals
14.7.5.1.4.
Antiparasitic
14.7.5.2.
Italy
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.5.2.1.
Oral
14.7.5.2.2.
Topical
14.7.5.2.3.
Injectable
14.7.5.2.4.
Others
14.7.5.3.
Italy
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.5.3.1.
Respiratory
Infections
14.7.5.3.2.
Urinary
Tract Infections (UTIs)
14.7.5.3.3.
Skin and
Soft Tissue Infections
14.7.5.3.4.
Sexually
Transmitted Infections (STIs)
14.7.5.3.5.
Gastrointestinal
Infections
14.7.5.3.6.
Central
Nervous System Infections
14.7.5.3.7.
Others
14.7.5.4.
Italy
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
14.7.5.4.1.
Broad-spectrum
14.7.5.4.2.
Narrow-spectrum
14.7.5.5.
Italy
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
14.7.5.5.1.
Hospitals
and Clinics
14.7.5.5.2.
Homecare
14.7.5.5.3.
Research
Institutes
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
14.7.6.1.1.
Antibacterials
14.7.6.1.2.
Antivirals
14.7.6.1.3.
Antifungals
14.7.6.1.4.
Antiparasitic
14.7.6.2.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.6.2.1.
Oral
14.7.6.2.2.
Topical
14.7.6.2.3.
Injectable
14.7.6.2.4.
Others
14.7.6.3.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.7.6.3.1.
Respiratory
Infections
14.7.6.3.2.
Urinary
Tract Infections (UTIs)
14.7.6.3.3.
Skin and
Soft Tissue Infections
14.7.6.3.4.
Sexually
Transmitted Infections (STIs)
14.7.6.3.5.
Gastrointestinal
Infections
14.7.6.3.6.
Central
Nervous System Infections
14.7.6.3.7.
Others
14.7.6.4.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
14.7.6.4.1.
Broad-spectrum
14.7.6.4.2.
Narrow-spectrum
14.7.6.5.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End User
14.7.6.5.1.
Hospitals
and Clinics
14.7.6.5.2.
Homecare
14.7.6.5.3.
Research
Institutes
14.7.6.6.
Nordic
Countries Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.6.6.1.
Denmark
14.7.6.6.2.
Finland
14.7.6.6.3.
Iceland
14.7.6.6.4.
Sweden
14.7.6.6.5.
Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.7.7.1.1.
Antibacterials
14.7.7.1.2.
Antivirals
14.7.7.1.3.
Antifungals
14.7.7.1.4.
Antiparasitic
14.7.7.2.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.7.2.1.
Oral
14.7.7.2.2.
Topical
14.7.7.2.3.
Injectable
14.7.7.2.4.
Others
14.7.7.3.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.7.7.3.1.
Respiratory
Infections
14.7.7.3.2.
Urinary
Tract Infections (UTIs)
14.7.7.3.3.
Skin and
Soft Tissue Infections
14.7.7.3.4.
Sexually
Transmitted Infections (STIs)
14.7.7.3.5.
Gastrointestinal
Infections
14.7.7.3.6.
Central
Nervous System Infections
14.7.7.3.7.
Others
14.7.7.4.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
14.7.7.4.1.
Broad-spectrum
14.7.7.4.2.
Narrow-spectrum
14.7.7.5.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
14.7.7.5.1.
Hospitals
and Clinics
14.7.7.5.2.
Homecare
14.7.7.5.3.
Research
Institutes
14.7.7.6.
Benelux
Union Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.7.6.1.
Belgium
14.7.7.6.2.
The
Netherlands
14.7.7.6.3.
Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
14.7.8.1.1.
Antibacterials
14.7.8.1.2.
Antivirals
14.7.8.1.3.
Antifungals
14.7.8.1.4.
Antiparasitic
14.7.8.2.
Rest of
Europe Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.8.2.1.
Oral
14.7.8.2.2.
Topical
14.7.8.2.3.
Injectable
14.7.8.2.4.
Others
14.7.8.3.
Rest of
Europe Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.7.8.3.1.
Respiratory
Infections
14.7.8.3.2.
Urinary
Tract Infections (UTIs)
14.7.8.3.3.
Skin and
Soft Tissue Infections
14.7.8.3.4.
Sexually
Transmitted Infections (STIs)
14.7.8.3.5.
Gastrointestinal
Infections
14.7.8.3.6.
Central
Nervous System Infections
14.7.8.3.7.
Others
14.7.8.4.
Rest of
Europe Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
14.7.8.4.1.
Broad-spectrum
14.7.8.4.2.
Narrow-spectrum
14.7.8.5.
Rest of
Europe Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
14.7.8.5.1.
Hospitals
and Clinics
14.7.8.5.2.
Homecare
14.7.8.5.3.
Research
Institutes
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Drug Class
14.8.3. By Route of Administration
14.8.4. By Disease Indication
14.8.5. By Spectrum of Activity
14.8.6. By End User
15. Asia Pacific Antimicrobial Therapeutics
Market Analysis and Forecasts, 2023 - 2031
15.1. Overview
15.1.1. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn)
15.2. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.2.1. Antibacterials
15.2.2. Antivirals
15.2.3. Antifungals
15.2.4. Antiparasitic
15.3. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Oral
15.3.2. Topical
15.3.3. Injectable
15.3.4. Others
15.4. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
15.4.1. Respiratory Infections
15.4.2. Urinary Tract Infections (UTIs)
15.4.3. Skin and Soft Tissue Infections
15.4.4. Sexually Transmitted Infections (STIs)
15.4.5. Gastrointestinal Infections
15.4.6. Central Nervous System Infections
15.4.7. Others
15.5. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
15.5.1. Broad-spectrum
15.5.2. Narrow-spectrum
15.6. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End User
15.6.1. Hospitals and Clinics
15.6.2. Homecare
15.6.3. Research Institutes
15.7. Asia Pacific Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.1.1.1.
Antibacterials
15.7.1.1.2.
Antivirals
15.7.1.1.3.
Antifungals
15.7.1.1.4.
Antiparasitic
15.7.1.2.
China
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.1.2.1.
Oral
15.7.1.2.2.
Topical
15.7.1.2.3.
Injectable
15.7.1.2.4.
Others
15.7.1.3.
China
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.1.3.1.
Respiratory
Infections
15.7.1.3.2.
Urinary
Tract Infections (UTIs)
15.7.1.3.3.
Skin and
Soft Tissue Infections
15.7.1.3.4.
Sexually
Transmitted Infections (STIs)
15.7.1.3.5.
Gastrointestinal
Infections
15.7.1.3.6.
Central
Nervous System Infections
15.7.1.3.7.
Others
15.7.1.4.
China
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
15.7.1.4.1.
Broad-spectrum
15.7.1.4.2.
Narrow-spectrum
15.7.1.5.
China
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.5.1.
Hospitals
and Clinics
15.7.1.5.2.
Homecare
15.7.1.5.3.
Research
Institutes
15.7.2. Japan
15.7.2.1.
Japan
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.2.1.1.
Antibacterials
15.7.2.1.2.
Antivirals
15.7.2.1.3.
Antifungals
15.7.2.1.4.
Antiparasitic
15.7.2.2.
Japan
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.2.2.1.
Oral
15.7.2.2.2.
Topical
15.7.2.2.3.
Injectable
15.7.2.2.4.
Others
15.7.2.3.
Japan
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.2.3.1.
Respiratory
Infections
15.7.2.3.2.
Urinary
Tract Infections (UTIs)
15.7.2.3.3.
Skin and
Soft Tissue Infections
15.7.2.3.4.
Sexually
Transmitted Infections (STIs)
15.7.2.3.5.
Gastrointestinal
Infections
15.7.2.3.6.
Central
Nervous System Infections
15.7.2.3.7.
Others
15.7.2.4.
Japan
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
15.7.2.4.1.
Broad-spectrum
15.7.2.4.2.
Narrow-spectrum
15.7.2.5.
Japan
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.2.5.1.
Hospitals
and Clinics
15.7.2.5.2.
Homecare
15.7.2.5.3.
Research
Institutes
15.7.3. India
15.7.3.1.
India Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.3.1.1.
Antibacterials
15.7.3.1.2.
Antivirals
15.7.3.1.3.
Antifungals
15.7.3.1.4.
Antiparasitic
15.7.3.2.
India
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.3.2.1.
Oral
15.7.3.2.2.
Topical
15.7.3.2.3.
Injectable
15.7.3.2.4.
Others
15.7.3.3.
India
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.3.3.1.
Respiratory
Infections
15.7.3.3.2.
Urinary
Tract Infections (UTIs)
15.7.3.3.3.
Skin and
Soft Tissue Infections
15.7.3.3.4.
Sexually
Transmitted Infections (STIs)
15.7.3.3.5.
Gastrointestinal
Infections
15.7.3.3.6.
Central
Nervous System Infections
15.7.3.3.7.
Others
15.7.3.4.
India
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
15.7.3.4.1.
Broad-spectrum
15.7.3.4.2.
Narrow-spectrum
15.7.3.5.
India
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.3.5.1.
Hospitals
and Clinics
15.7.3.5.2.
Homecare
15.7.3.5.3.
Research
Institutes
15.7.4. New Zealand
15.7.4.1.
New
Zealand Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
15.7.4.1.1.
Antibacterials
15.7.4.1.2.
Antivirals
15.7.4.1.3.
Antifungals
15.7.4.1.4.
Antiparasitic
15.7.4.2.
New
Zealand Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.4.2.1.
Oral
15.7.4.2.2.
Topical
15.7.4.2.3.
Injectable
15.7.4.2.4.
Others
15.7.4.3.
New
Zealand Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.7.4.3.1.
Respiratory
Infections
15.7.4.3.2.
Urinary
Tract Infections (UTIs)
15.7.4.3.3.
Skin and
Soft Tissue Infections
15.7.4.3.4.
Sexually
Transmitted Infections (STIs)
15.7.4.3.5.
Gastrointestinal
Infections
15.7.4.3.6.
Central
Nervous System Infections
15.7.4.3.7.
Others
15.7.4.4.
New
Zealand Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
15.7.4.4.1.
Broad-spectrum
15.7.4.4.2.
Narrow-spectrum
15.7.4.5.
New
Zealand Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
End User
15.7.4.5.1.
Hospitals
and Clinics
15.7.4.5.2.
Homecare
15.7.4.5.3.
Research
Institutes
15.7.5. Australia
15.7.5.1.
Australia
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.5.1.1.
Antibacterials
15.7.5.1.2.
Antivirals
15.7.5.1.3.
Antifungals
15.7.5.1.4.
Antiparasitic
15.7.5.2.
Australia
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.5.2.1.
Oral
15.7.5.2.2.
Topical
15.7.5.2.3.
Injectable
15.7.5.2.4.
Others
15.7.5.3.
Australia
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.5.3.1.
Respiratory
Infections
15.7.5.3.2.
Urinary
Tract Infections (UTIs)
15.7.5.3.3.
Skin and
Soft Tissue Infections
15.7.5.3.4.
Sexually
Transmitted Infections (STIs)
15.7.5.3.5.
Gastrointestinal
Infections
15.7.5.3.6.
Central
Nervous System Infections
15.7.5.3.7.
Others
15.7.5.4.
Australia
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
15.7.5.4.1.
Broad-spectrum
15.7.5.4.2.
Narrow-spectrum
15.7.5.5.
Australia
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
15.7.5.5.1.
Hospitals
and Clinics
15.7.5.5.2.
Homecare
15.7.5.5.3.
Research
Institutes
15.7.6. South Korea
15.7.6.1.
South
Korea Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.7.6.1.1.
Antibacterials
15.7.6.1.2.
Antivirals
15.7.6.1.3.
Antifungals
15.7.6.1.4.
Antiparasitic
15.7.6.2.
South
Korea Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.6.2.1.
Oral
15.7.6.2.2.
Topical
15.7.6.2.3.
Injectable
15.7.6.2.4.
Others
15.7.6.3.
South
Korea Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.7.6.3.1.
Respiratory
Infections
15.7.6.3.2.
Urinary
Tract Infections (UTIs)
15.7.6.3.3.
Skin and
Soft Tissue Infections
15.7.6.3.4.
Sexually
Transmitted Infections (STIs)
15.7.6.3.5.
Gastrointestinal
Infections
15.7.6.3.6.
Central
Nervous System Infections
15.7.6.3.7.
Others
15.7.6.4.
South
Korea Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
15.7.6.4.1.
Broad-spectrum
15.7.6.4.2.
Narrow-spectrum
15.7.6.5.
South
Korea Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.6.5.1.
Hospitals
and Clinics
15.7.6.5.2.
Homecare
15.7.6.5.3.
Research
Institutes
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.7.7.1.1.
Antibacterials
15.7.7.1.2.
Antivirals
15.7.7.1.3.
Antifungals
15.7.7.1.4.
Antiparasitic
15.7.7.2.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.7.2.1.
Oral
15.7.7.2.2.
Topical
15.7.7.2.3.
Injectable
15.7.7.2.4.
Others
15.7.7.3.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.7.7.3.1.
Respiratory
Infections
15.7.7.3.2.
Urinary
Tract Infections (UTIs)
15.7.7.3.3.
Skin and
Soft Tissue Infections
15.7.7.3.4.
Sexually
Transmitted Infections (STIs)
15.7.7.3.5.
Gastrointestinal
Infections
15.7.7.3.6.
Central
Nervous System Infections
15.7.7.3.7.
Others
15.7.7.4.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
15.7.7.4.1.
Broad-spectrum
15.7.7.4.2.
Narrow-spectrum
15.7.7.5.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.7.5.1.
Hospitals
and Clinics
15.7.7.5.2.
Homecare
15.7.7.5.3.
Research
Institutes
15.7.7.6.
Southeast
Asia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1.
Indonesia
15.7.7.6.2.
Thailand
15.7.7.6.3.
Malaysia
15.7.7.6.4.
Singapore
15.7.7.6.5.
Rest of
Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Drug Class
15.7.8.1.1.
Antibacterials
15.7.8.1.2.
Antivirals
15.7.8.1.3.
Antifungals
15.7.8.1.4.
Antiparasitic
15.7.8.2.
Rest of
Asia Pacific Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.8.2.1.
Oral
15.7.8.2.2.
Topical
15.7.8.2.3.
Injectable
15.7.8.2.4.
Others
15.7.8.3.
Rest of
Asia Pacific Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
15.7.8.3.1.
Respiratory
Infections
15.7.8.3.2.
Urinary
Tract Infections (UTIs)
15.7.8.3.3.
Skin and
Soft Tissue Infections
15.7.8.3.4.
Sexually
Transmitted Infections (STIs)
15.7.8.3.5.
Gastrointestinal
Infections
15.7.8.3.6.
Central
Nervous System Infections
15.7.8.3.7.
Others
15.7.8.4.
Rest of
Asia Pacific Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Spectrum of Activity
15.7.8.4.1.
Broad-spectrum
15.7.8.4.2.
Narrow-spectrum
15.7.8.5.
Rest of
Asia Pacific Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By End User
15.7.8.5.1.
Hospitals
and Clinics
15.7.8.5.2.
Homecare
15.7.8.5.3.
Research
Institutes
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Drug Class
15.8.3. By Route of Administration
15.8.4. By Disease Indication
15.8.5. By Spectrum of Activity
15.8.6. By End User
16. Middle East and Africa Antimicrobial
Therapeutics Market Analysis and Forecasts, 2023 - 2031
16.1. Overview
16.1.1. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn)
16.2. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.2.1. Antibacterials
16.2.2. Antivirals
16.2.3. Antifungals
16.2.4. Antiparasitic
16.3. Middle East and Africa Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.3.1. Oral
16.3.2. Topical
16.3.3. Injectable
16.3.4. Others
16.4. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease Indication
16.4.1. Respiratory Infections
16.4.2. Urinary Tract Infections (UTIs)
16.4.3. Skin and Soft Tissue Infections
16.4.4. Sexually Transmitted Infections (STIs)
16.4.5. Gastrointestinal Infections
16.4.6. Central Nervous System Infections
16.4.7. Others
16.5. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
16.5.1. Broad-spectrum
16.5.2. Narrow-spectrum
16.6. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
16.6.1. Hospitals and Clinics
16.6.2. Homecare
16.6.3. Research Institutes
16.7. Middle East and Africa Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
16.7.1.1.1.
Antibacterials
16.7.1.1.2.
Antivirals
16.7.1.1.3.
Antifungals
16.7.1.1.4.
Antiparasitic
16.7.1.2.
Saudi
Arabia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.1.2.1.
Oral
16.7.1.2.2.
Topical
16.7.1.2.3.
Injectable
16.7.1.2.4.
Others
16.7.1.3.
Saudi
Arabia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
16.7.1.3.1.
Respiratory
Infections
16.7.1.3.2.
Urinary
Tract Infections (UTIs)
16.7.1.3.3.
Skin and
Soft Tissue Infections
16.7.1.3.4.
Sexually
Transmitted Infections (STIs)
16.7.1.3.5.
Gastrointestinal
Infections
16.7.1.3.6.
Central
Nervous System Infections
16.7.1.3.7.
Others
16.7.1.4.
Saudi
Arabia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
16.7.1.4.1.
Broad-spectrum
16.7.1.4.2.
Narrow-spectrum
16.7.1.5.
Saudi
Arabia Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
16.7.1.5.1.
Hospitals
and Clinics
16.7.1.5.2.
Homecare
16.7.1.5.3.
Research
Institutes
16.7.2. UAE
16.7.2.1.
UAE
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.2.1.1.
Antibacterials
16.7.2.1.2.
Antivirals
16.7.2.1.3.
Antifungals
16.7.2.1.4.
Antiparasitic
16.7.2.2.
UAE
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.2.2.1.
Oral
16.7.2.2.2.
Topical
16.7.2.2.3.
Injectable
16.7.2.2.4.
Others
16.7.2.3.
UAE
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.2.3.1.
Respiratory
Infections
16.7.2.3.2.
Urinary
Tract Infections (UTIs)
16.7.2.3.3.
Skin and
Soft Tissue Infections
16.7.2.3.4.
Sexually
Transmitted Infections (STIs)
16.7.2.3.5.
Gastrointestinal
Infections
16.7.2.3.6.
Central
Nervous System Infections
16.7.2.3.7.
Others
16.7.2.4.
UAE
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
16.7.2.4.1.
Broad-spectrum
16.7.2.4.2.
Narrow-spectrum
16.7.2.5.
UAE
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.2.5.1.
Hospitals
and Clinics
16.7.2.5.2.
Homecare
16.7.2.5.3.
Research
Institutes
16.7.3. Egypt
16.7.3.1.
Egypt
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.3.1.1.
Antibacterials
16.7.3.1.2.
Antivirals
16.7.3.1.3.
Antifungals
16.7.3.1.4.
Antiparasitic
16.7.3.2.
Egypt
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.3.2.1.
Oral
16.7.3.2.2.
Topical
16.7.3.2.3.
Injectable
16.7.3.2.4.
Others
16.7.3.3.
Egypt
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.3.3.1.
Respiratory
Infections
16.7.3.3.2.
Urinary
Tract Infections (UTIs)
16.7.3.3.3.
Skin and
Soft Tissue Infections
16.7.3.3.4.
Sexually
Transmitted Infections (STIs)
16.7.3.3.5.
Gastrointestinal
Infections
16.7.3.3.6.
Central
Nervous System Infections
16.7.3.3.7.
Others
16.7.3.4.
Egypt Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
16.7.3.4.1.
Broad-spectrum
16.7.3.4.2.
Narrow-spectrum
16.7.3.5.
Egypt
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.3.5.1.
Hospitals
and Clinics
16.7.3.5.2.
Homecare
16.7.3.5.3.
Research
Institutes
16.7.4. Kuwait
16.7.4.1.
Kuwait
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.4.1.1.
Antibacterials
16.7.4.1.2.
Antivirals
16.7.4.1.3.
Antifungals
16.7.4.1.4.
Antiparasitic
16.7.4.2.
Kuwait
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.4.2.1.
Oral
16.7.4.2.2.
Topical
16.7.4.2.3.
Injectable
16.7.4.2.4.
Others
16.7.4.3.
Kuwait
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.4.3.1.
Respiratory
Infections
16.7.4.3.2.
Urinary
Tract Infections (UTIs)
16.7.4.3.3.
Skin and
Soft Tissue Infections
16.7.4.3.4.
Sexually
Transmitted Infections (STIs)
16.7.4.3.5.
Gastrointestinal
Infections
16.7.4.3.6.
Central
Nervous System Infections
16.7.4.3.7.
Others
16.7.4.4.
Kuwait
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
16.7.4.4.1.
Broad-spectrum
16.7.4.4.2.
Narrow-spectrum
16.7.4.5.
Kuwait
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
16.7.4.5.1.
Hospitals
and Clinics
16.7.4.5.2.
Homecare
16.7.4.5.3.
Research
Institutes
16.7.5. South Africa
16.7.5.1.
South
Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Drug Class
16.7.5.1.1.
Antibacterials
16.7.5.1.2.
Antivirals
16.7.5.1.3.
Antifungals
16.7.5.1.4.
Antiparasitic
16.7.5.2.
South
Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.5.2.1.
Oral
16.7.5.2.2.
Topical
16.7.5.2.3.
Injectable
16.7.5.2.4.
Others
16.7.5.3.
South
Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
16.7.5.3.1.
Respiratory
Infections
16.7.5.3.2.
Urinary
Tract Infections (UTIs)
16.7.5.3.3.
Skin and
Soft Tissue Infections
16.7.5.3.4.
Sexually
Transmitted Infections (STIs)
16.7.5.3.5.
Gastrointestinal
Infections
16.7.5.3.6.
Central
Nervous System Infections
16.7.5.3.7.
Others
16.7.5.4.
South
Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By
Spectrum of Activity
16.7.5.4.1.
Broad-spectrum
16.7.5.4.2.
Narrow-spectrum
16.7.5.5.
South
Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End
User
16.7.5.5.1.
Hospitals
and Clinics
16.7.5.5.2.
Homecare
16.7.5.5.3.
Research
Institutes
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.6.1.1.
Antibacterials
16.7.6.1.2.
Antivirals
16.7.6.1.3.
Antifungals
16.7.6.1.4.
Antiparasitic
16.7.6.2.
Rest of
Middle East & Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.6.2.1.
Oral
16.7.6.2.2.
Topical
16.7.6.2.3.
Injectable
16.7.6.2.4.
Others
16.7.6.3.
Rest of
Middle East & Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.7.6.3.1.
Respiratory
Infections
16.7.6.3.2.
Urinary
Tract Infections (UTIs)
16.7.6.3.3.
Skin and
Soft Tissue Infections
16.7.6.3.4.
Sexually
Transmitted Infections (STIs)
16.7.6.3.5.
Gastrointestinal
Infections
16.7.6.3.6.
Central
Nervous System Infections
16.7.6.3.7.
Others
16.7.6.4.
Rest of
Middle East & Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and
Forecasts, By Spectrum of Activity
16.7.6.4.1.
Broad-spectrum
16.7.6.4.2.
Narrow-spectrum
16.7.6.5.
Rest of
Middle East & Africa Antimicrobial Therapeutics Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.6.5.1.
Hospitals
and Clinics
16.7.6.5.2.
Homecare
16.7.6.5.3.
Research
Institutes
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Drug Class
16.8.3. By Route of Administration
16.8.4. By Disease Indication
16.8.5. By Spectrum of Activity
16.8.6. By End User
17. Latin America Antimicrobial Therapeutics
Market Analysis and Forecasts, 2023 - 2031
17.1. Overview
17.1.1. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn)
17.2. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Drug Class
17.2.1. Antibacterials
17.2.2. Antivirals
17.2.3. Antifungals
17.2.4. Antiparasitic
17.3. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.3.1. Oral
17.3.2. Topical
17.3.3. Injectable
17.3.4. Others
17.4. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Disease Indication
17.4.1. Respiratory Infections
17.4.2. Urinary Tract Infections (UTIs)
17.4.3. Skin and Soft Tissue Infections
17.4.4. Sexually Transmitted Infections (STIs)
17.4.5. Gastrointestinal Infections
17.4.6. Central Nervous System Infections
17.4.7. Others
17.5. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Spectrum of Activity
17.5.1. Broad-spectrum
17.5.2. Narrow-spectrum
17.6. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By End User
17.6.1. Hospitals and Clinics
17.6.2. Homecare
17.6.3. Research Institutes
17.7. Latin America Antimicrobial Therapeutics
Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
17.7.1.1.1.
Antibacterials
17.7.1.1.2.
Antivirals
17.7.1.1.3.
Antifungals
17.7.1.1.4.
Antiparasitic
17.7.1.2.
Brazil Antimicrobial
Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.1.2.1.
Oral
17.7.1.2.2.
Topical
17.7.1.2.3.
Injectable
17.7.1.2.4.
Others
17.7.1.3.
Brazil
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.7.1.3.1.
Respiratory
Infections
17.7.1.3.2.
Urinary
Tract Infections (UTIs)
17.7.1.3.3.
Skin and
Soft Tissue Infections
17.7.1.3.4.
Sexually
Transmitted Infections (STIs)
17.7.1.3.5.
Gastrointestinal
Infections
17.7.1.3.6.
Central
Nervous System Infections
17.7.1.3.7.
Others
17.7.1.4.
Brazil
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
17.7.1.4.1.
Broad-spectrum
17.7.1.4.2.
Narrow-spectrum
17.7.1.5.
Brazil
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.5.1.
Hospitals
and Clinics
17.7.1.5.2.
Homecare
17.7.1.5.3.
Research
Institutes
17.7.2. Argentina
17.7.2.1.
Argentina
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drug Class
17.7.2.1.1.
Antibacterials
17.7.2.1.2.
Antivirals
17.7.2.1.3.
Antifungals
17.7.2.1.4.
Antiparasitic
17.7.2.2.
Argentina
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.2.2.1.
Oral
17.7.2.2.2.
Topical
17.7.2.2.3.
Injectable
17.7.2.2.4.
Others
17.7.2.3.
Argentina
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.7.2.3.1.
Respiratory
Infections
17.7.2.3.2.
Urinary
Tract Infections (UTIs)
17.7.2.3.3.
Skin and
Soft Tissue Infections
17.7.2.3.4.
Sexually
Transmitted Infections (STIs)
17.7.2.3.5.
Gastrointestinal
Infections
17.7.2.3.6.
Central
Nervous System Infections
17.7.2.3.7.
Others
17.7.2.4.
Argentina
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By Spectrum
of Activity
17.7.2.4.1.
Broad-spectrum
17.7.2.4.2.
Narrow-spectrum
17.7.2.5.
Argentina
Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts, By End User
17.7.2.5.1.
Hospitals
and Clinics
17.7.2.5.2.
Homecare
17.7.2.5.3.
Research
Institutes
17.7.3. Rest of Latin America
17.7.3.1.
Rest of
Latin America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Drug Class
17.7.3.1.1.
Antibacterials
17.7.3.1.2.
Antivirals
17.7.3.1.3.
Antifungals
17.7.3.1.4.
Antiparasitic
17.7.3.2.
Rest of
Latin America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
17.7.3.2.1.
Oral
17.7.3.2.2.
Topical
17.7.3.2.3.
Injectable
17.7.3.2.4.
Others
17.7.3.3.
Rest of
Latin America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
17.7.3.3.1.
Respiratory
Infections
17.7.3.3.2.
Urinary
Tract Infections (UTIs)
17.7.3.3.3.
Skin and
Soft Tissue Infections
17.7.3.3.4.
Sexually
Transmitted Infections (STIs)
17.7.3.3.5.
Gastrointestinal
Infections
17.7.3.3.6.
Central
Nervous System Infections
17.7.3.3.7.
Others
17.7.3.4.
Rest of
Latin America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By Spectrum of Activity
17.7.3.4.1.
Broad-spectrum
17.7.3.4.2.
Narrow-spectrum
17.7.3.5.
Rest of
Latin America Antimicrobial Therapeutics Market Revenue (US$ Mn) and Forecasts,
By End User
17.7.3.5.1.
Hospitals
and Clinics
17.7.3.5.2.
Homecare
17.7.3.5.3.
Research
Institutes
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Drug Class
17.8.3. By Route of Administration
17.8.4. By Disease Indication
17.8.5. By Spectrum of Activity
17.8.6. By End User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2022
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. AbbVie Inc.
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Allergan
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. AstraZeneca
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. Bayer AG
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Bristol Myers Squibb Company
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. F. Hoffmann-La
Roche Ltd
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Gilead Sciences, Inc.
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. GSK plc
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Johnson & Johnson Services, Inc.
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. Lilly
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Merck & Co., Inc.
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. Novartis AG
19.12.1. Company Details
19.12.2. Company Overview
19.12.3. Product Offerings
19.12.4. Key Developments
19.12.5. Financial Analysis
19.12.6. SWOT Analysis
19.12.7. Business Strategies
19.13. Pfizer Inc.
19.13.1. Company Details
19.13.2. Company Overview
19.13.3. Product Offerings
19.13.4. Key Developments
19.13.5. Financial Analysis
19.13.6. SWOT Analysis
19.13.7. Business Strategies
19.14. Sanofi
19.14.1. Company Details
19.14.2. Company Overview
19.14.3. Product Offerings
19.14.4. Key Developments
19.14.5. Financial Analysis
19.14.6. SWOT Analysis
19.14.7. Business Strategies
19.15. Other Market Participants
20. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.